Haemostaseology

Posted in News on April 2nd, 2014

The accolade for the DiPat protein pattern analysis the stem cell transplant, the transmission of blood-forming stem cells from the bone marrow or blood from healthy donors, often represents the only way to cure Leukemia patients. The acute Graft-versus-host disease (GvHD) is one of the life-threatening complications of the transplant. GvHD occurs at approximately 35% to 85% of transplanted patients. This graft-versus host-reaction which are transmitted immune cells of the donor (graft) against the body of the receiver (host) and this attack. The clinical symptoms of this reaction is evident primarily in skin, liver and intestines.

The early recognition of this rejection is crucial to treat life-threatening complications. So far, the diagnosis was based mainly on the medical assessment of the clinical symptoms and the histological assessment of surgically removed tissue of the affected organs. Scientists of the biotechnology company mosaiques diagnostics (www.mosaiques-diagnostics.com) now in a prospective, multicenter study with the clinic for Haematology, Haemostaseology and Oncology and stem cell transplantation at the medical school Hannover (MHH, 250.html) noticed: the innovative urine-protein analysis diagnosed GvHD already 14 days before the first clinical symptoms, and objectively measurable. Even more. The protein pattern analysis provides information about the risk of GvHD present, to develop towards the critical, life-threatening grade III and IV in addition from the outset. (Grade I and II are quite desirable from a therapeutic perspective.) In the framework of the renowned in the journal leukemia”published study (www.nature.com/ leu/journal/vaop/naam/abs/leu2013210a.html) stammzelltransplantierten with 423 Leukemia patients from five transplant centers continue to impressively showed that the protein pattern analysis in addition to the first measurable early ster ID is ultimately even a best Therapeutic choice and – all degrees of severity enables secure GvHD-monitoring and control of measures initiated. This non-invasive method enables a targeted therapy for the first time and prevents life-threatening skin, liver and intestinal complications,”Dr. Jochen Metzger summarizes mosaiques Diagnostics.

Tags: ,
This post is under “News” and has no respond so far.
If you enjoy this article, make sure you subscribe to my RSS Feed.


© 2010-2017 Uruguay Biotech All Rights Reserved